EQ - Nano-Cap Equillium Shares Fall After Patchy Hair Loss Study Data | Benzinga
Equillium Inc. (NASDAQ:EQ) announced Tuesday topline data from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with alopecia areata.
Alopecia is an autoimmune disease that attacks the body’s hair follicles, causing patchy hair loss.
The primary objectives of the study were to evaluate the safety and tolerability profile of EQ101 and signs of efficacy using Severity of Alopecia Tool (SALT) scores, where a score of 100 represents total scalp hair loss and a score of 0 represents no scalp hair loss.
Study results demonstrated a favorable safety and tolerability profile. No serious adverse events and improvements in SALT scores were above the published historically low placebo response rates.
Of all subjects that ...